Service Génétique Médicale, CHU de Bordeaux, Bordeaux, France.
Département de Génétique, Hôpital Robert Debré, Paris, France.
Pigment Cell Melanoma Res. 2017 Jan;30(6):563-570. doi: 10.1111/pcmr.12608. Epub 2017 Oct 20.
Hermansky-Pudlak syndrome (HPS), first described in 1959, is a rare form of syndromic oculocutaneous albinism associated with bleeding diathesis and in some cases pulmonary fibrosis and granulomatous colitis. All 10 HPS types are caused by defects in vesicle trafficking of lysosome-related organelles (LRO) proteins. The HPS5 protein associates with HPS3 and HPS6 to form the biogenesis of lysosome-related organelles complex-2 (BLOC-2). Here, we report the clinical and genetic data of 11 patients with HPS-5 analyzed in our laboratory. We report 11 new pathogenic variants. The 11 patients present with ocular features that are typical for albinism, with mild hypopigmentation, and with no other major complication, apart from a tendency to bleed. HPS-5 therefore appears as a mild form of HPS, which is often clinically undistinguishable from mild oculocutaneous or ocular forms of albinism. Molecular analysis is therefore required to establish the diagnosis of this mild HPS form, which has consequences in terms of prognosis and of clinical management of the patients.
Hermansky-Pudlak 综合征(HPS)于 1959 年首次描述,是一种罕见的伴有出血倾向的综合征性眼皮肤白化病,在某些情况下还伴有肺纤维化和肉芽肿性结肠炎。所有 10 种 HPS 类型均由溶酶体相关细胞器(LRO)蛋白囊泡运输缺陷引起。HPS5 蛋白与 HPS3 和 HPS6 结合形成溶酶体相关细胞器生物发生复合物 2(BLOC-2)。在这里,我们报告了在我们实验室分析的 11 例 HPS-5 患者的临床和遗传数据。我们报告了 11 个新的致病性变异。这 11 名患者表现出典型的白化病眼部特征,色素减退程度较轻,除了有出血倾向外,没有其他主要并发症。因此,HPS-5 表现为一种轻度 HPS,在临床上常与轻度眼皮肤或眼型白化病难以区分。因此,需要进行分子分析以明确这种轻度 HPS 形式的诊断,这对患者的预后和临床管理有影响。